Pharm.D., Ph.D., BCPS, FCCP, Clinical Pharmacogenetics Implementation Consortium (CPIC) Co-PI and Director, St. Jude Children's Research Hospital
Biography
The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of volunteers and a small, dedicated staff who are interested in facilitating the use of pharmacogenetic tests results for patient care. One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs. CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines publications. To date, CPIC has published 26 gene-based clinical guidelines. CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated. CPIC started as a shared project between PharmGKB, and the Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB. Dr. Caudle oversees all Clinical Pharmacogenomic implementation Consortium-related projects and the CPIC guideline development process including the coordination of the guideline-writing committees, the guideline evidence reviews, and the writing of the guideline manuscript and supplement. Dr. Caudle is also involved in clinical implementation of pharmacogenetics at St. Jude Children’s Research Hospital. She has published over 50 manuscripts in the area of pharmacogenomics. Dr. Caudle received a bachelor of science from Middle Tennessee State University and her Pharm D and PhD in Pharmaceutical Sciences from University of Tennessee Health Science Center where she is currently an affiliate Asst. Professor. She has completed an ASHP-accredited PGY2 residency at Le Bonheur Children’s Hospital and is a board‐certified Pharmacotherapy Specialist.
Session Abstract – PMWC 2023 Silicon Valley
Track 1 - January 27 9.00 A.M.-4.15 P.M.
Track Co-Chair:
Mary Relling, St. Jude
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.
- PMWC 2023 PGx Award Ceremony:
Pioneer Honoree: Dan Roden, Vanderbilt University Medical Center
Luminary Honoree: Kelly E. Caudle, St. Jude
- Fireside Chat:
PMWC 2023 Pioneer Honoree Dan Roden, Vanderbilt University Medical Center with Mary Relling, St. Jude - Keynote by PMWC 2023 Luminary Honoree:
- Kelly E. Caudle, St. Jude - Fireside Chat:
Chair: Damon Hostin, Illumina
- Howard McLeod, Intermountain Health - Laboratory Testing and Reports
Chair: Kristy Crooks, University of Colorado
- Ann M. Moyer, Mayo Clinic
- Stuart Scott, Stanford University
- Implementation of PGx at UCSF
- Bani Tamraz, UCSF
- From Economics to Reimbursement (PANEL)
Chair: Sara Rogers, American Society of Pharmacovigilance
- Stirling Bryan, The University of British Columbia
- Ray Stultz, Optum
- Gabriel Bien-Willner, Palmetto GBA
- Policy Efforts to Address Barriers to PGx Adoption
Chair: Kristine Ashcraft, Invitae
- Pam Traxel, ACS CAN - PGx Practice Liability
Chair: Dan Hertz, University of Michigan
- Anthony Morreale, VA, San Diego
- Karen Merritt, Patient Advocate - Diversity, Equity, and Inclusion in Pharmacogenomics Implementation
- Carlos Bustamante, Galatea Bio
- Kathy Giacomini, UCSF - Implementation of PGx Program & PGx Clinic Services in a Large Rural Healthcare Setting
- April Schultz, Sanford
